cover
Article Per Year (5 Year)
All
Home Page
OAI Link
Editorial Team
Contact
Reviewer
Google Scholar
Contact Name
Farisa Luthfiana
Contact Email
lppmuta45@uta45jakarta.ac.id
Phone
+6282218999015
Journal Mail Official
lppmuta45@uta45jakarta.ac.id
Editorial Address
Fakultas Farmasi, Universitas 17 Agustus 1945 Jakarta Jl. Sunter Permai Raya, Sunter Podomoro, Jakarta 14350
Location
Kota adm. jakarta utara,
Dki jakarta
INDONESIA
SOCIAL CLINICAL PHARMACY INDONESIA JOURNAL
Published by Universitas 17 Agustus 1945 Jakarta
ISSN : -     EISSN : 25028413     DOI : https://doi.org/10.52447/scpij.v7i1
Core Subject : Health, Social,
Health Professions Medicine & Pharmacology Public Health Social Sciences
Social Clinical Pharmacy Indonesia Journal (SCPIJ) is a scientific journal managed by the Faculty of Pharmacy Universitas 17 Agustus 1945 Jakarta, which is published twice a year (April and October). SCPIJ is a scientific research journal in the field of community service with articles that have never been published online or in print before. SCPIJ aims to disseminate conceptual thoughts or ideas and research results that have been achieved in the fields of pharmacy and health, Regulatory Affairs and Pharmaceutical Marketing Research, Pharmaceutical Care,Pharmacotheraphy, Pharmacoepydemology, Pharmacogenetic, Rational Therapeutics, Evidence-Based Practice, Health Services Research, Medication Management, Drug Interactions, Drug Utilization, Drug Prescribing, Drug Information. The results of the service published in this journal are in the form of experimental and non-experimental service.
Arjuna Subject : Profesi Kesehatan - Farmasi
Articles 114 Documents
 8   9   10   11   12 
EVALUASI PEMANTAUAN TERAPI OBAT PADA PASIEN GERIATRI DENGAN TIA, SINDROMA DISPEPSIA, DISLIPIDEMIA, DIABETES MELITUS TIPE 2 DI RUMAH SAKIT “X” DI JAKARTA melasari, wulan panduwi
SOCIAL CLINICAL PHARMACY INDONESIA JOURNAL Vol 10, No 2 (2025)
Publisher : Universitas 17 Agustus 1945 Jakarta

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.52447/scpij.v10i2.9022

Abstract

Pemantauan terapi obat (PTO) dilakukan untuk memastikan keamanan, efektivitas, dan ketepatan penggunaan obat pada pasien. Pelaksanaan pemantauan terapi obat terlihat pada kasus seorang pasien yang datang ke Poli Saraf dengan keluhan tidak ada nafsu makan, bicara pelo, begah, mual, muntah, dan keluarga mengatakan pasien tidak mau makan sejak pulang perawatan dari Unit Stroke. Pasien didiagnosa Transient ischemic attack (TIA), sindroma dispepsia, dislipidemia, dan diabetes melitus tipe 2.  Tujuan pemantauan terapi obat adalah untuk mengidentifikasi Drug Related Problems (DRPs) pada pasien geriatri dengan diagnosa Transient ischemic attack (TIA), sindroma dispepsia, dislipidemia, dan diabetes melitus tipe 2. Metode yang dilakukan dalam pemantauan terapi obat ini adalah secara observasional dengan pengambilan data melalui catatan perkembangan pasien terintergrasi dari Sistem Informasi Manajemen Rumah Sakit (SIMRS), analisis data menggunakan format SOAP, identifikasi Drug Related Problems (DRPs) berdasarkan klasifikasi PCNE (Pharmaceutical Care Network Europe) V9.1, dan melakukan visite secara langsung serta koordinasi profesional pemberi asuhan terkait intervensi pengobatan. Berdasarkan pemantauan terapi obat diperoleh drug related problems berupa adanya interaksi obat dengan kategori mayor antara Donepezil HCl dengan Risperidone yang dapat mengakibatkan meningkatnya risiko perpanjangan interval QT dan torsade de pointes. Setiap intervensi telah dicantumkan di catatan perkembangan pasien terintegrasi dan telah didiskusikan dengan dokter sehingga hasil intervensi dapat diimplementasikan.Kata kunci: Pemantauan terapi obat, Transient ischemic attack, Sindroma dispepsia, Dislipidemia, Diabetes melitus tipe 2
Determinan Dan Pola Konsumsi Antibiotik Pada Balita Dengan Diare di Indonesia: Analisis Data Demographic Health Survey 2017 Maylinda, Tashya Dhela; Yulianto, Rivai Endra Dwi
SOCIAL CLINICAL PHARMACY INDONESIA JOURNAL Vol 10, No 2 (2025)
Publisher : Universitas 17 Agustus 1945 Jakarta

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.52447/scpij.v10i2.9258

Abstract

Diarrhea is still the second leading cause of death for children under five years of age. Deaths of children under five years due to diarrhea are caused by unsafe water, inadequate sanitation, and hygiene. Socio-demographic characteristics, environment, behavior, and parenting practices are factors associated with diarrhea in children under five years in Indonesia. The use of antibiotics in the treatment of diarrhea needs more attention. Antibiotic resistance can occur if its use is not based on a proper diagnosis. This study was conducted to examine the factors that influence the incidence of diarrhea in children under five years of age. This study also looked at the prevalence of treatment centers for diarrhea patients and the use of antibiotics for the treatment of diarrhea in children under five years of age. The data used is cross-sectional data on children under five living in households in Indonesia taken from the 2017 DHS survey through data collections and survey reports. Descriptive analyzes were performed on survey reports and datasets related to demographics, the prevalence of diarrheal diseases, and the use of antibiotics for the treatment of diarrhea. Significance analysis was conducted to see whether the selected variables had an effect on the incidence of diarrhea in children under five years of age. Gender, age, location of residence (urban or rural), wealth level, mother's education level and the main material of the house floor are significant factors influencing the incidence of diarrhea in children under five years. Puskesmas is a place to seek treatment for diarrhea which is most frequently visited by children under five years old (20.99%). 10.9% of pediatric patients with diarrhea visited more than one health facility. Private hospitals are the places that most often give antibiotics to children under five years of age who have diarrhea (25%). Antibiotics were given not only by licensed health care facilities but also by other places visited by respondents, namely traditional birth attendants, grocery stores, and other sources.
ANALYSIS OF CHEMOTHERAPY COSTS IN BREAST CANCER PATIENTS PARTICIPATING BPJS AT DHARMAIS CANCER HOSPITAL JAKARTA Piter, Piter; Astiani, Rangki; Monica, Kristin; Permatasari, Yuri
SOCIAL CLINICAL PHARMACY INDONESIA JOURNAL Vol 10, No 2 (2025)
Publisher : Universitas 17 Agustus 1945 Jakarta

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.52447/scpij.v10i2.7773

Abstract

This study aims to find out how much chemotherapy costs for inpatient breast cancer chemotherapy patients participating in BPJS and whether there is a difference in real hospital costs compared to INA-CBGs rates. This research is a descriptive, observational study taken from secondary data, in the form of medical record data, laboratory data, INA-CBGs e-claim data and financial data on patient medical costs in accordance with the inclusion and exclusion criteria totaling 100 patient data. Data analysis uses One Sample T-test to see whether there is a significant difference between real costs and INA-CBGs rates. Based on the results of the One Sample T-test, it shows that there is a significant difference. According to the statistical results, a significance of p<0.005 was obtained in class 3 and there was no significant difference in class 1 or class 2. The average cost that breast cancer patients have to pay for each procedure chemotherapy, severity level I Rp. 7,129,348, severity level II Rp. 9,323,275 and severity level III Rp. 9,037,426.
REVIEW ARTIKEL: WAWASAN FARMAKOGENOMIK DAN BIOINFORMATIKA VARIAN GEN ACE DAN PENGARUHNYA TERHADAP RESPONS INHIBITOR ACE PADA HIPERTENSI Anggraeni, Ria; Astiani, Rangki
SOCIAL CLINICAL PHARMACY INDONESIA JOURNAL Vol 10, No 2 (2025)
Publisher : Universitas 17 Agustus 1945 Jakarta

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.52447/scpij.v10i2.9109

Abstract

Respons terhadap terapi antihipertensi berbasis angiotensin-converting enzyme inhibitors (ACEIs) bervariasi antar individu, yang sebagian besar dipengaruhi oleh faktor genetik. Gen ACE memiliki sejumlah polimorfisme yang dapat memengaruhi kadar enzim dan efektivitas terapi. Penelitian ini bertujuan mengeksplorasi hubungan antara variasi genetik pada gen ACE dan respons terhadap kaptopril, lisinopril, ramipril, dan enalapril pada pasien hipertensi. Penelitian ini menggunakan pendekatan bioinformatika dan farmakogenomik dengan menganalisis data dari PharmGKB, Ensembl, dan GTEx Portal. Polimorfisme genetik dianalisis untuk mengevaluasi keterkaitannya dengan efektivitas ACEI menggunakan pendekatan statistik deskriptif. Empat polimorfisme nukleotida tunggal (SNP) pada gen ACE ditemukan berasosiasi dengan respons terhadap ACEI. Varian rs4291 dan rs1799752 dikaitkan dengan efikasi kaptopril, di mana genotipe AA menunjukkan penurunan keparahan gagal ginjal. Varian rs1799752 juga terkait dengan lisinopril dan enalapril, dengan genotipe DD memberikan penurunan tekanan darah yang lebih besar. Selain itu, rs4359 dan rs4344 berkorelasi dengan efektivitas ramipril, terutama pada genotipe CC+TT dan AA+GG. Kesimpulan: Variasi genetik pada gen ACE berperan dalam menentukan respons terhadap terapi ACEI. Pendekatan farmakogenetik berpotensi meningkatkan efikasi dan keamanan pengobatan antihipertensi

Page 12 of 12 | Total Record : 114

 8   9   10   11   12 

Filter by Year

2016 2025


Reset
Filter By Issues
All Issue Vol 10, No 2 (2025) Vol 10, No 1 (2025) Vol 8, No 2 (2023) Vol 8, No 1 (2023) Vol 7, No 2 (2022) Vol 7, No 1 (2022) Vol 6, No 2 (2021) Vol 6, No 1 (2021) Vol 5, No 2 (2020) Vol 5, No 1 (2020) Vol 4, No 2 (2019) Vol 4, No 1 (2019) Vol 3, No 2 (2018) Vol 2, No 2 (2017) Vol 2, No 1 (2017) Vol 1, No 2 (2016) Vol 1, No 1 (2016) More Issue